P-484 - The influence of depot antipsychotic treatment on the occurrence of MB. parkinsoni caused by medicaments- case report

2012 ◽  
Vol 27 ◽  
pp. 1
Author(s):  
Z. Golubovic ◽  
Z. Barac-Otasevic ◽  
A. Raznatovic ◽  
T. Perunovic-Jovanovic ◽  
V. Gazivoda ◽  
...  
Keyword(s):  
Case Report ◽  
Antipsychotic Treatment ◽  
Depot Antipsychotic

scholarly journals S206. ARIPIPRAZOLE LONG-ACTING INJECTABLE IN SCHIZOPHRENIA DURING PREGNANCY: A CASE REPORT

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S117-S117
Author(s):  
Eva Sole ◽  
Juan Ignacio Duran ◽  
Sara Lera ◽  
Anna Torres ◽  
Susana Andres ◽  
...  
Keyword(s):  
Case Report ◽  
Mental Disorder ◽  
Clinical Case ◽  
Psychotic Disorders ◽  
Hospital Admissions ◽  
Treatment Compliance ◽  
Antipsychotic Treatment ◽  
Pregnancy And Postpartum ◽  
Long Acting ◽  
Psychiatric Complications

Abstract Background Long-acting injectable (LAI) antipsychotics provide some advantages in treatment compliance of psychotic disorders. However, information about their effects during pregnancy is still very limited. We expose a clinical case of aripiprazole LAI use in a pregnant woman diagnosed of schizophrenia. Methods A non-systematic review using Pubmed was conducted using the following terms: schizophrenia, pregnancy, aripiprazole and aripiprazole LAI. A clinical record review was performed for the clinical case report. Results We report the case of a 30-year-old woman diagnosed of schizophrenia. She required several hospital admissions in the past because of the mental disorder and the lack of treatment adherence, what was the consequence of having no insight of illness and her pregnancy desires. She was initially treated with risperidone, suffering from some adverse effects like prolactine elevation and amenorrhea. In the last hospital admission, she started treatment with aripiprazol 20mg, having a good tolerability and being finally changed into aripiprazole LAI 400mg/28days. No incidences were reported and stability was achieved. After five months, she became pregnant and started being followed up in the Perinatal Mental Health Unit that belongs to the same hospital. The severity of the mental disorder and her stability at that moment made psychiatrists; obstetricians and patient decide to keep the antipsychotic treatment with subsequent appointments. The goal was to supervise psychopathology and blood tests during pregnancy. Prolactine was in physiologic levels and there were no obstetric complications. She finally delivered at 41 gestational weeks to a 3465g baby girl (Apgar 1’: 9 Apgar 5’: 10). No neonatal complications were reported. The Stafford interview was also administered in order to explore her social, obstetric and psychological background as well as possible psychiatric complications due to pregnancy and puerperium. No psychiatric complications were reported. Postpartum Bounding Questionnaire was also administered. No bounding disorder was detected. Discussion Pregnancy and postpartum are periods that carry a high risk of illness onset or recurrence in women with severe mental disorders, such as schizophrenia. Having a good control of the symptoms may prevent from risks to both patient and child, due to the important influence that exists on the development of the baby and the mother-infant relationship.

Indication of depot antipsychotic treatment in the view of slovak psychiatrists

2016 ◽  
Vol 33 (S1) ◽  
pp. S553-S553
Author(s):  
M. Zelman
Keyword(s):  
Negative Symptoms ◽  
Atypical Antipsychotics ◽  
Young Patients ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Depot Antipsychotic ◽  
Treatment Research ◽  
Competing Interest ◽  
Oral Antipsychotic ◽  
Depot Form

With the increasing number of atypical antipsychotics in depot form, there emerges question about plus and cons of their use in schizophrenia patients. We focused on the opinion of Slovak psychiatrists about use of this treatment in some specific situations of schizophrenia treatment. Research was realized via questionnaire on psychiatrists (n = 47) from ambulant and hospital care, during one conference in June 2015. First part of the questionnaire was focused on the preference of oral or depot form of antipsychotic treatment. Depot form would be indicated by psychiatrists (in more than 89%) when low compliance, anosognosia or frequent episodes. On the contrary, oral antipsychotic treatment is preferred in young patients or employed patients. The type of symptoms (e.g. positive, negative) has relatively small impact on the preference of treatment, where the preferences of each type were the lowest (fewer than 36%). According to the opinion of psychiatrists, depot antipsychotic treatment is not suitable in first episode of disorder (according to 81% of respondents), otherwise in second or third episode it would not be chosen by 6% of asked psychiatrists.From the aspects of the choice between atypical or typical depot, atypical antipsychotics in depot form were favored when presence of adverse reactions (80%), occurrence of negative symptoms (65%) and short duration of disorder (58%). Typical depot was preferred by psychiatrists in patients with chronic states.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Pulmonary embolism in a patient receiving risperidone and paliperidone: A case report and review of the literature

2013 ◽  
Vol 3 (3) ◽  
pp. 144-147
Author(s):  
Ariane Casey ◽  
Marianne Saitz ◽  
Paul R. Swaim
Keyword(s):  
Pulmonary Embolism ◽  
Case Report ◽  
Venous Thromboembolism ◽  
Atypical Antipsychotic ◽  
Antipsychotic Treatment ◽  
Review Of The Literature ◽  
Long Acting

Several cases of pulmonary embolism (PE) have been associated with antipsychotic treatment. We report a case of an otherwise healthy 27-year old male who developed a PE after receiving paliperidone long acting injection. The patient received risperidone long acting injection for over 3 months before initiating paliperidone, but was switched incorrectly. After 3 weeks on paliperidone long acting injection the patient developed a PE requiring hospitalization and a course of anticoagulation. A review of atypical antipsychotic-induced venous thromboembolism is discussed.

Prolactine borderline, a case report

2016 ◽  
Vol 33 (S1) ◽  
pp. S619-S619 ◽  
Author(s):  
N. Salgado ◽  
B. Macias ◽  
S. Benavente ◽  
R. Ruiz
Keyword(s):  
Case Report ◽  
Antipsychotic Drugs ◽  
Borderline Personality ◽  
Good Option ◽  
Common Side Effect ◽  
Antipsychotic Treatment ◽  
Minimum Effective Dose ◽  
Menstrual Disorders ◽  
History Of ◽  
Competing Interest

IntroductionIt is known that antipsychotic drugs can increase prolactinaemia, we report a case in which the use of aripiprazole after treatment with paliperidone helped regaining normality levels.Case reportDuring treatment with PALiperidone12 mg/day the patient, a 27-year-old female diagnosed with borderline personality disorder, developed hyperprolactinaemia with galactorrhea and menstrual disorders. During hospitalization, aripiprazole is introduced while paliperidone is progressively decreased. Antipsychotic were prescribed because delusions of reference and auditory pseudo-hallucinations arose suddenly in a woman without history of previous psychotic breaks. Before treatment with aripiprazole, prolactinaemia was 156,96 ng/mL (pregnancy test was negative) and after stopping, paliperidone was 23,60 ng/mL.DiscussionIf hyperprolactinaemia symptoms appeared (galactorrhea…), aripiprazole is a good option if antipsychotic treatment is required. In this case, paliperidone was decreased slowly, while aripiprazole was increased, until minimum effective dose was reached.ConclusionsHyperprolactinaemia is a common side effect in antipsychotic treatments and if symptoms appeared aripiprazole is a good option.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals 4CPS-175 Optimisation of antipsychotic treatment in a patient undergoing dialysis: a case report

2019 ◽  
Author(s):  
C González Martín ◽  
J Ruiz Gutierrez ◽  
A Diez Alcantara ◽  
T Delgado Expósito ◽  
M Ruiz de Hoyos ◽  
...  
Keyword(s):  
Case Report ◽  
Antipsychotic Treatment

Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity

2014 ◽  
Vol 29 (2) ◽  
Author(s):  
Enrique López-Torres ◽  
Ágnes Süveges ◽  
Eva M. Peñas-LLedó ◽  
Alvaro Doña ◽  
Pedro Dorado ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Enzyme ◽  
Antipsychotic Treatment

scholarly journals Surgical Treatment of Tardive Dystonia in Nepal: A Case Report

2016 ◽  
Vol 12 (2) ◽  
pp. 81-84
Author(s):  
Resha Shrestha ◽  
Takaomi Taira ◽  
Pranaya Shrestha ◽  
Pravesh Rajbhanari ◽  
Sudan Dhakal ◽  
...  
Keyword(s):  
Case Report ◽  
Deep Brain Stimulation ◽  
Surgical Treatment ◽  
Brain Stimulation ◽  
Antipsychotic Treatment ◽  
Long Period ◽  
Tardive Dystonia ◽  
First Case ◽  
Surgical Treatments ◽  
Deep Brain

Tardive dystonia is a subtype of dystonia which is seen in patients receiving antipsychotic treatment for long period. Medical treatment of tardive dystonia is very complex and many cases do not respond well to currently available treatment and sometimes can be irreversible. Surgical treatments like pallidotomy and Deep Brain Stimulation (DBS) have shown some promising results. We report this case of Tardive Dystonia who benefitted from Pallidotomy. We believe this is the first case in Nepal.Nepal Journal of Neuroscience 12:81-84, 2015

Guidelines for depot antipsychotic treatment in schizophrenia

1998 ◽  
Vol 8 (1) ◽  
pp. 55-66 ◽  
Author(s):  
John M Kane ◽  
Eugenio Aguglia ◽  
A.Carlo Altamura ◽  
José Luis Ayuso Gutierrez ◽  
Nicoletta Brunello ◽  
...  
Keyword(s):  
Antipsychotic Treatment ◽  
Depot Antipsychotic

Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report

2018 ◽  
Vol 54 (2) ◽  
pp. 150-156 ◽  
Author(s):  
Eva-Maria Pichler ◽  
Wolfram Kawohl ◽  
Erich Seifritz ◽  
Patrik Roser
Keyword(s):  
Case Report ◽  
Female Patient ◽  
Tourette Syndrome ◽  
Therapeutic Potential ◽  
Antipsychotic Treatment ◽  
Pharmacological Properties ◽  
Severity Scale ◽  
Treatment Resistant ◽  
Beneficial Effects ◽  
Tic Severity

Objectives Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We report the case of a female patient suffering from treatment-resistant Tourette syndrome. Methods Guideline-directed antipsychotic treatment with risperidone and aripiprazole as well as pure delta-9-tetrahydrocannabinol had no significant effect on Tourette syndrome symptomatology. Results Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale. Conclusions It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol.

Sign in / Sign up

Export Citation Format

Share Document